[Neonatal sepsis caused by Streptococcus agalactiae. What should be done?]. 1998

R Montero Alonso, and F Barbadillo Izquierdo, and S Ansó Oliván, and M Marrero Calvo, and I Carpintero Martín, and E Sastre Huerta, and B Alonso Alvarez
Sección Neonatal (Servicio de Pediatría), Hospital General Yagüe, Burgos.

OBJECTIVE Within the common pathogenic flora responsible for neonatal sepsis, streptococci group B (SGB) is the most frequently found etiological agent. The fact that it is a frequent colonizer of the female perigenital area has resulted in a whole host of detection and eradication strategies via preventative measures applied to the pregnant woman to eliminate vertical transmission to the newborn. METHODS We present a revision of SGB sepsis and our protocol based on the intrapartum treatment of those pregnant women with risk factors and the study in the newborn at risk of infection with early detection of particles of Latex in urine for SGB (Slidex Strepto B bioMerieux), as well as the customary analytical and bacteriological tests. We have also revised the different strategies in medical scientific publications and several neonatal units for the management of this infection and compare this with our protocol. RESULTS During the period 1986-1996 the incidence of SGB sepsis was 0.9/1,000 (19 cases), with an incidence of neonatal sepsis of 4.08/1,000. The incidence of sepsis caused by Streptococcus agalactiae in our environment is low, although it has increased from 15.9% to 28% comparing the first five years with the following six years, with a fatality rate of 10.5%. We believe that the most effective strategy for this problem is intrapartum identification and treatment of the pregnant woman at risk and early diagnosis of the newborn resulting from this pregnancy. CONCLUSIONS We based our strategy on two vias, intrapartum treatment of mothers included in the high risk infection group and in the neonatal unit by early routine detection of SGB in urine. We have obtained a low incidence rate, low mortality rate and avoid false negatives of carrier mothers.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000667 Ampicillin Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic. Penicillin, Aminobenzyl,Amcill,Aminobenzylpenicillin,Ampicillin Sodium,Ampicillin Trihydrate,Antibiotic KS-R1,Omnipen,Pentrexyl,Polycillin,Ukapen,Aminobenzyl Penicillin,Antibiotic KS R1,KS-R1, Antibiotic,Sodium, Ampicillin,Trihydrate, Ampicillin
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013290 Streptococcal Infections Infections with bacteria of the genus STREPTOCOCCUS. Group A Strep Infection,Group A Streptococcal Infection,Group A Streptococcal Infections,Group B Strep Infection,Group B Streptococcal Infection,Group B Streptococcal Infections,Infections, Streptococcal,Infection, Streptococcal,Streptococcal Infection

Related Publications

R Montero Alonso, and F Barbadillo Izquierdo, and S Ansó Oliván, and M Marrero Calvo, and I Carpintero Martín, and E Sastre Huerta, and B Alonso Alvarez
June 1980, Revista clinica espanola,
R Montero Alonso, and F Barbadillo Izquierdo, and S Ansó Oliván, and M Marrero Calvo, and I Carpintero Martín, and E Sastre Huerta, and B Alonso Alvarez
September 2007, Harefuah,
R Montero Alonso, and F Barbadillo Izquierdo, and S Ansó Oliván, and M Marrero Calvo, and I Carpintero Martín, and E Sastre Huerta, and B Alonso Alvarez
January 1970, Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology,
R Montero Alonso, and F Barbadillo Izquierdo, and S Ansó Oliván, and M Marrero Calvo, and I Carpintero Martín, and E Sastre Huerta, and B Alonso Alvarez
December 1974, Proceedings of the Royal Society of Medicine,
R Montero Alonso, and F Barbadillo Izquierdo, and S Ansó Oliván, and M Marrero Calvo, and I Carpintero Martín, and E Sastre Huerta, and B Alonso Alvarez
February 1997, Physician executive,
R Montero Alonso, and F Barbadillo Izquierdo, and S Ansó Oliván, and M Marrero Calvo, and I Carpintero Martín, and E Sastre Huerta, and B Alonso Alvarez
July 2013, Journal of medical ethics,
R Montero Alonso, and F Barbadillo Izquierdo, and S Ansó Oliván, and M Marrero Calvo, and I Carpintero Martín, and E Sastre Huerta, and B Alonso Alvarez
April 2013, MMW Fortschritte der Medizin,
R Montero Alonso, and F Barbadillo Izquierdo, and S Ansó Oliván, and M Marrero Calvo, and I Carpintero Martín, and E Sastre Huerta, and B Alonso Alvarez
November 1997, Science (New York, N.Y.),
R Montero Alonso, and F Barbadillo Izquierdo, and S Ansó Oliván, and M Marrero Calvo, and I Carpintero Martín, and E Sastre Huerta, and B Alonso Alvarez
January 2017, Journal of the California Dental Association,
R Montero Alonso, and F Barbadillo Izquierdo, and S Ansó Oliván, and M Marrero Calvo, and I Carpintero Martín, and E Sastre Huerta, and B Alonso Alvarez
August 2011, Archivos argentinos de pediatria,
Copied contents to your clipboard!